Prof Markus Möhler speaks to ecancer in an online interview for the virtual ESMO 2020 meeting about the first results from the CheckMate 649 study.
The study looked at nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for non-HER-2-positive advanced gastric cancer, gastro-oesophageal junction cancer, or oesophageal cancer.
Prof Möhler reports that the results suggest nivolumab plus chemotherapy could be a new first-line standard of care treatment option for these patients.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.